Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Bone Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Bone Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Unable to determine if Bone Therapeutics is high growth as no earnings estimate data is available.
Bone Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Bone Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Bone Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Bone Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Bone Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Bone Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 1.2x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Thomas Lienard, MBA, has been Chief Executive Officer of Bone Therapeutics SA since October 27, 2016. Mr. Lienard served as Interim Chief Executive Officer at Bone Therapeutics SA from October 11, 2016 to October 27, 2016 and served as its Chief Business Officer from November 9, 2015 October 10, 2016. Mr. Lienard assumes responsibility for activities regarding business development, business operations and strategic planning at Bone Therapeutics SA. Mr. Lienard has over 15 years of national and international sales and marketing experience in the pharmaceutical industry. Prior to joining Bone Therapeutics, Mr. Lienard served at Lundbeck, where he served as Managing Director for Belgium and Luxemburg and was vital to the launch of several products. He led a team of up to 80 employees, generating over EUR 50 million in sales. He served at Eli Lilly and Company, where he served various positions in sales and marketing in Europe and the US, including Sales Director Belgium in 2010. Mr. Lienard started his career in 1999 as consultant at McKinsey & Company. He has been Director of Bone Therapeutics SA since October 27, 2016. Mr. Lienard graduated from Solvay Brussels School of Economics and Management as Master in Business Engineering in 1999 and obtained a Master of Business Administration (MBA) degree from Harvard Business School in Boston in 2004.
Thomas's compensation has increased whilst company is loss making.
Thomas's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Bone Therapeutics management team is less than 2 years, this suggests a new team.
CEO & Director
CFO & Executive Director
Chief Scientific & Technology Officer
Gunther De Backer
Head of Corporate Communications & Investor Relations
Chief Regulatory Officer
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Bone Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors
Chairman of the Board
CEO & Director
CFO & Executive Director
Independent Director & Member of Scientific Advisory Board
Bone Therapeutics SA, a biotechnology company, engages in the development of cell therapy products for orthopedics and bone diseases. Its products include ALLOB, an allogeneic cell therapy product, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion; and PREOB, an autologous bone cell therapy product that is in Phase III development for the treatment of osteonecrosis of the hip. Bone Therapeutics SA was founded in 2006 and is based in Gosselies, Belgium.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.